Case Study: AI & Software as a Medical Device (SaMD) Regulatory Strategy

Executive Summary

Artificial intelligence is reshaping healthcare at an unprecedented pace. Machine learning, predictive analytics, cloud computing, wearable integration, and digital biomarkers are enabling software to perform functions that were once possible only through traditional medical devices or direct clinical interpretation. Healthcare organizations increasingly rely on software to organize complex information, assist clinicians, improve workflow efficiency, and support more informed decision-making.

Innovation, however, has outpaced regulatory familiarity for many developers. Technology companies often possess extraordinary software engineering talent but limited experience navigating FDA expectations, international software standards, cybersecurity requirements, clinical validation, and quality management systems.

An innovative digital health company developing AI-powered Software as a Medical Device (SaMD) engaged E&E Medicals after recognizing that its technical achievements alone would not be sufficient to support regulatory authorization. Although the platform demonstrated promising performance during early evaluations, leadership lacked clarity regarding product classification, software documentation, clinical evidence, algorithm lifecycle management, cybersecurity, and regulatory submission planning.

Rather than approaching the engagement as a documentation project, E&E Medicals developed a comprehensive regulatory strategy that integrated software engineering, artificial intelligence governance, clinical science, risk management, cybersecurity, and quality system development into a single commercialization roadmap.

The result was a regulatory-ready development program capable of supporting future FDA engagement while establishing a scalable framework for software evolution, international expansion, and long-term lifecycle management.

Company Background

The client was a venture-backed digital health company founded by software engineers, physicians, artificial intelligence specialists, and data scientists. Its mission was to improve healthcare decision-making through advanced machine learning capable of identifying clinically meaningful patterns within large volumes of patient information.

The software platform integrated data from multiple sources, including electronic health records, connected medical devices, laboratory information, and patient-generated health data. Sophisticated algorithms transformed these inputs into structured outputs intended to assist healthcare professionals in evaluating patient information more efficiently.

The platform incorporated:

• Cloud-based architecture

• Machine learning algorithms

• Predictive analytics

• Data visualization

• Clinical workflow integration

• Mobile accessibility

• Secure data management

• Continuous software updates

Although technically advanced, leadership understood that healthcare software requires a level of regulatory discipline significantly different from conventional commercial software.

The Regulatory Challenge

At the beginning of the engagement, company leadership believed that software development and regulatory compliance could proceed independently until commercialization approached.

E&E Medicals explained that this assumption represented one of the greatest risks facing digital health companies.

Unlike consumer applications, software as a medical device must demonstrate that software development, risk management, verification, validation, cybersecurity, usability, and quality management have been integrated throughout the product lifecycle.

Attempting to reconstruct documentation after software development is complete often proves expensive, time-consuming, and technically difficult.

The organization therefore committed to embedding regulatory science directly into its development process.

Determining Regulatory Status

The first objective involved determining whether the software met the regulatory definition of a medical device.

E&E Medicals conducted a structured assessment evaluating:

• Intended use

• Clinical functionality

• User population

• Healthcare setting

• Decision-support characteristics

• Level of user independence

• Risk profile

• Existing FDA classifications

• International guidance

Rather than focusing solely on software features, consultants analyzed how users would rely upon the information generated by the system.

This evaluation clarified the appropriate regulatory pathway while helping product management refine marketing claims and product positioning.

Building the Regulatory Roadmap

Following classification, E&E Medicals developed a regulatory master plan aligned with software development activities.

Rather than treating regulatory affairs as a separate workstream, the roadmap synchronized engineering milestones with quality, clinical, cybersecurity, and regulatory deliverables.

Major milestones included:

• Intended use refinement

• Regulatory pathway confirmation

• Software Development Plan

• Risk Management Plan

• Cybersecurity strategy

• Clinical evaluation planning

• Human factors engineering

• Verification and validation planning

• Quality Management System implementation

• FDA interaction strategy

• Commercial readiness planning

This integrated roadmap allowed technical teams to understand how engineering decisions influenced future regulatory submissions.

Implementing IEC 62304 Software Lifecycle Processes

Software lifecycle management formed the foundation of the engagement.

E&E Medicals worked closely with software architects and engineering managers to implement development processes aligned with IEC 62304, the internationally recognized standard for medical device software lifecycle processes.

Development activities were organized into clearly documented phases:

• Software development planning

• Requirements management

• Software architecture

• Detailed design

• Unit implementation

• Integration testing

• System testing

• Release management

• Maintenance

• Problem resolution

Traceability was established between user requirements, software requirements, architecture, implementation, testing, and release documentation.

This disciplined approach significantly improved development transparency while supporting future regulatory review.

Integrating Risk Management Throughout Development

Artificial intelligence introduces unique categories of risk beyond those encountered in traditional software.

Using the principles of ISO 14971, E&E Medicals facilitated multidisciplinary risk analyses examining technical, clinical, operational, and human factors considerations.

Potential hazards included:

• Incorrect algorithm outputs

• False-positive results

• False-negative results

• Incomplete input data

• User misunderstanding

• Interface design errors

• Data integrity failures

• Cybersecurity threats

• Software updates introducing unintended changes

• Cloud service interruptions

Rather than documenting risks after software completion, hazard analysis became an ongoing engineering activity influencing software architecture, testing priorities, user interface design, and clinical validation.

Cybersecurity by Design

Healthcare software increasingly depends upon cloud connectivity, remote access, interoperability, and continuous software updates.

Recognizing these realities, E&E Medicals emphasized cybersecurity as a core engineering discipline rather than a final validation activity.

Working alongside software developers, cybersecurity specialists implemented structured processes addressing:

• Threat modeling

• Authentication

• Access control

• Encryption

• Secure software updates

• Vulnerability management

• Logging and monitoring

• Incident response planning

• Third-party software management

• Penetration testing

Cybersecurity documentation was aligned with current FDA expectations and recognized industry best practices.

Human Factors Engineering

One of the most underestimated aspects of SaMD development involves user interaction.

A technically accurate algorithm can still present unacceptable clinical risk if users misunderstand outputs or operate the software incorrectly.

E&E Medicals therefore coordinated comprehensive usability engineering activities evaluating:

• User interface clarity

• Workflow integration

• Alarm presentation

• Data visualization

• Information hierarchy

• Navigation efficiency

• Error prevention

• User comprehension

• Clinical workflow compatibility

Representative healthcare professionals participated in simulated use evaluations to identify opportunities for interface improvement before commercialization.

Clinical Validation Strategy

Algorithm performance alone is insufficient to establish regulatory confidence.

Clinical validation was therefore designed to demonstrate that software outputs remained meaningful within real-world healthcare environments.

Clinical studies evaluated:

• Algorithm accuracy

• Clinical relevance

• User interpretation

• Workflow efficiency

• Consistency across representative patient populations

• Reliability over time

• Clinical benefit

• Safety outcomes

Statistical methodologies were selected collaboratively with clinicians and biostatisticians to ensure that evidence would support intended regulatory claims.

AI Lifecycle Governance and Change Management

One of the defining characteristics of artificial intelligence is its potential to evolve over time.

Rather than treating software releases as isolated events, E&E Medicals established governance processes supporting long-term algorithm management.

The framework addressed:

• Model version control

• Training data governance

• Performance monitoring

• Validation of software updates

• Documentation of algorithm modifications

• Risk assessment before release

• Verification of continued safety and effectiveness

• Controlled deployment

For AI-enabled software where future modifications were anticipated, E&E Medicals also developed a strategy consistent with FDA's evolving framework for Predetermined Change Control Plans (PCCPs). A PCCP outline provides, in advance, the types of software changes that may be implemented after authorization and the methods used to validate those changes, helping ensure a structured approach to lifecycle management while maintaining regulatory oversight.

Preparing for Regulatory Submission

As development matured, E&E Medicals coordinated preparation of documentation supporting future regulatory interactions.

The submission strategy incorporated:

• Device description

• Intended use

• Software architecture

• Risk management documentation

• Cybersecurity documentation

• Software lifecycle evidence

• Verification reports

• Validation reports

• Clinical evidence

• Human factors documentation

• Quality Management System documentation

• Labeling strategy

Every section was reviewed to ensure consistency between engineering documentation, clinical evidence, risk management, and intended claims.

Rather than assembling disconnected reports, the submission presented a unified scientific narrative demonstrating that software development had been conducted within a mature, controlled quality framework.

Organizational Transformation

Perhaps the most enduring outcome involved organizational maturity.

Engineering teams gained greater appreciation for regulatory science. Regulatory specialists became more deeply integrated into software planning. Clinical experts contributed earlier to product development. Quality personnel participated throughout software lifecycle activities rather than only during release preparation.

This cross-functional collaboration significantly improved communication, reduced development risk, and strengthened product quality.

Outcome

By the conclusion of the engagement, the client possessed far more than a regulatory submission strategy.

The organization had implemented internationally recognized software lifecycle processes, integrated risk management throughout development, strengthened cybersecurity, established AI governance practices, enhanced usability engineering, developed a robust clinical validation strategy, and built a quality management framework capable of supporting future innovation.

Leadership no longer viewed regulatory affairs as a barrier to innovation but as a strategic discipline that accelerated commercialization by reducing uncertainty and improving product quality.

Business Impact

The engagement generated value across technical, regulatory, commercial, and organizational dimensions.

Development teams experienced fewer late-stage design changes because regulatory expectations had been incorporated from the outset. Investors gained confidence in the company's commercialization strategy. Product managers developed more realistic launch plans. Engineering leaders benefited from improved documentation, traceability, and software quality.

Perhaps most importantly, the company established a scalable governance model capable of supporting future software releases, international market expansion, and evolving artificial intelligence technologies.

Why E&E Medicals Was Chosen

Artificial intelligence and software as a medical device represent one of the most dynamic intersections of healthcare, engineering, and regulation. Success requires more than software expertise or regulatory knowledge alone—it requires the ability to integrate technology, clinical science, quality systems, cybersecurity, risk management, and lifecycle governance into a unified development strategy.

E&E Medicals provides that integration

By combining expertise in FDA medical device regulation, software lifecycle management, AI governance, ISO 14971 risk management, IEC 62304, cybersecurity, human factors engineering, clinical validation, and global regulatory strategy, E&E Medicals helps innovators transform promising software concepts into regulatory-ready products capable of improving healthcare while meeting the expectations of regulators, clinicians, and patients.

‍